We demonstrated that activating CB2R by selective agonist JWH133 is a potential strategy for the treatment of pulmonary fibrosis because it can inhibit TGF-β1 induced lung fibroblasts proliferation, migration, collagen I and α-SMA expression. Here, ACTA1 is linked to pulmonary fibrosis.